AQST · Company research
Aquestive Therapeutics, Inc. Common Stock (AQST): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| $AQST stock is down 11% today. Here's what we see in our data. - Quiver Quantitative | $AQST stock is down 11% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 15, 2026 | neutral | 0 | 0.6 |
| Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 | Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for treating Type I allergic reactions and anaphylaxis. The FDA assigned a PDUFA goal date of March 16, 2027, classified as a Class 2 response. If approved, Anaphylm would be the first and only oral rescue medication for severe allergic reactions. The company is also advancing its Canadian regulatory submission planned for Q4 2026. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 | Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for treating Type I allergic reactions and anaphylaxis. The FDA assigned a PDUFA goal date of March 16, 2027, classified as a Class 2 response. If approved, Anaphylm would be the first and only oral rescue medication for severe allergic reactions. The company is also advancing its Canadian regulatory submission planned for Q4 2026. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Aquestive Therapeutics (AQST) Short Interest & Short Float | Updated Oct 2026 - MarketBeat | Aquestive Therapeutics (AQST) Short Interest & Short Float | Updated Oct 2026 MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success (NASDAQ:AQST) - Seeking Alpha | Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success (NASDAQ:AQST) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 30, 2026 | neutral | 0 | 0.6 |
| Aquestive Therapeutics (NasdaqGM:AQST) Stock Forecast & Analyst Predictions - Simply Wall Street | Aquestive Therapeutics (NasdaqGM:AQST) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 17, 2026 | neutral | 0 | 0.6 |
| Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus - Yahoo Finance | Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus Yahoo Finance | View source ↗ | Yahoo Finance | Sep 7, 2026 | neutral | 0 | 0.6 |
| Trading the Move, Not the Narrative: (AQST) Edition - Stock Traders Daily | Trading the Move, Not the Narrative: (AQST) Edition Stock Traders Daily | View source ↗ | Stock Traders Daily | Aug 27, 2026 | neutral | 0 | 0.6 |
| Aquestive Therapeutics: Potential Catalyst On The Horizon (NASDAQ:AQST) - Seeking Alpha | Aquestive Therapeutics: Potential Catalyst On The Horizon (NASDAQ:AQST) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 19, 2026 | neutral | 0 | 0.6 |
| Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan - Stock Titan | Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan Stock Titan | View source ↗ | Stock Titan | Aug 17, 2026 | neutral | 0 | 0.6 |
| Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission - Simply Wall Street | Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission Simply Wall Street | View source ↗ | Simply Wall Street | Aug 13, 2026 | neutral | 0 | 0.6 |
| Aquestive plans to resubmit postage-stamp-sized epinephrine film to FDA - Stock Titan | Aquestive plans to resubmit postage-stamp-sized epinephrine film to FDA Stock Titan | View source ↗ | Stock Titan | Aug 11, 2026 | neutral | 0 | 0.6 |
| Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance | Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 11, 2026 | neutral | 0 | 0.6 |
| AQST Forecast — Price Target — Prediction for 2027 - TradingView | AQST Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| $AQST stock is down 12% today. Here's what we see in our data. - Quiver Quantitative | $AQST stock is down 12% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 25, 2026 | neutral | 0 | 0.6 |
| Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? - Yahoo Finance | Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 24, 2026 | neutral | 0 | 0.6 |
| Insider Sale: Director at $AQST Sells 25,000 Shares | AQST Stock News - Quiver Quantitative | Insider Sale: Director at $AQST Sells 25,000 Shares | AQST Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.